Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Shilpa CDMO announced on November 3, 2026, that it is
"Peptides are becoming one of the most important areas of pharmaceutical development, but the opportunity goes well beyond current GLP-1 demand,” said
The new commercial line will join 3 existing
The company plans to add further 2-kL, 3-kL, and 5-kL SPPS reactors, which it said will establish one of the largest multi-ton peptide capacities in India.¹ The expanded operation will comprise 6 parallel current good manufacturing practice lines, allowing multiple programs to run independently. One of those lines is dedicated to cytotoxic peptide manufacturing using SPPS.¹
The platform supports SPPS, liquid-phase peptide synthesis (LPPS), and hybrid SPPS plus LPPS routes, as well as linear, cyclic, and branched peptides. Capabilities include unnatural and D-amino acids, lipidation, conjugation, and radioligand peptides.¹ More than 100 scientists and manufacturing specialists work in the peptide business, including an R&D team of more than 50 dedicated to peptide chemistries.¹
"For longer peptides, that can mean moving from solid-phase synthesis to a hybrid fragment-based route as volumes grow," said
The investment follows the launch of
Other CDMOs have also moved to expand peptide capabilities. On November 2, 2026, Samsung Biologics reported that 97.66% of
Most of the planned reactor capacity will be phased in over the next few years, and the company did not specify timelines for each reactor addition. Shilpa CDMO did not name customers, programs, or committed volumes for the new capacity. Its description of one of India's largest peptide capacities is the company's own characterization.
